Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immuno deficiency Virus

18

MMWR

August 5, 1994

43. Ogino MT, Dankner WM, Spector SA. Development and significance of zidovudine resistance
in children infected with human immunodeficiency virus. J Pediatr 1993;123:1-8.
44. St. Clair MH, Hartigan PM, Andrews JC, et al. Zidovudine resistance, syncytium-inducing phenotype and HIV disease progression in a case-control study. J Acquir Immune Defic Syndr
1993;6:891-7.
45. Boucher CAB, Van Leeuwen R, Kellam P, et al. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob
Agents Chemother 1993;37:1525-30.
46. Davison JS, Davison MC, Hay DM. Gastric emptying time in late pregnancy and labour. J
Obstet Gynaecol Br Commonw 1970;77:37.
47. Gerberding JL, Henderson DK. Management of occupational exposures to bloodborne pathogens: hepatitis B virus, hepatitis C virus, and human immunodeficiency virus. Clin Infect Dis
1992;14:1179-85.
48. Shih CC, Kaneshima H, Rabin L, et al. Postexposure prophylaxis with zidovudine suppresses
human immunodeficiency virus type I infection in SCID-hu mice in a time-dependent manner.
J Infect Dis 1991;163:625-7.
49. Morrey JD, Okleberry KM, Sidwell RW. Early-initiated zidovudine therapy prevents disease
but not low levels of persistent retrovirus in mice. J Acquir Immune Defic Syndr 1991;4:506-12.
50. Hayes KA, Lafrado LJ, Erickson JG, Marr JM, Mathes LE. Prophylactic ZDV therapy prevents
early viremia and lymphocyte decline but not primary infection in feline immunodeficiency
virus-inoculated cats. J Acquir Immune Defic Syndr 1993;6:127-34.
51. McCune JM, Namikawa R, Shih CC, Rabin L, Kaneshima H. Suppression of HIV-infection in
AZT-treated SCID-hu mice. Science 1990;247:564-6.
52. Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among
health care workers after occupational exposure to HIV-infected blood. Ann Intern Med
1993;118:913-9.
53. EI-Sadr W, Oleske JM, Agins BD, et al. Evaluation and management of early HIV infection.
Clinical practice guideline no. 7. AHCPR publication no. 94-0572. Rockville, MD: Agency for
Health Care Policy and Research, Public Health Service, US Department of Health and Human
Services, January 1994.
54. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center. Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child.
Pediatr Infect Dis J 1993;12:513-22.
55. CDC. Guidelines for prophylaxis against Pneumocystis cariniipneumonia for children infected
with human immunodeficiency virus. MMWR 1991;40 (No. RR-2).
56. CDC. 1993 Sexually transmitted diseases treatment guidelines. MMWR 1993;42 (No. RR-14).
57. Newell ML, Peckham CS. Working towards a European strategy for intervention to reduce
vertical transmission of HIV. Br J Obstet Gynaecol 1994;101:192-6.